A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

• Status: Terminated
• Trial end date: 2018-10-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this 2-stage, 2-cohort Phase 2 trial is to evaluate the safety and efficacy of talazoparib (also known as BMN 673) in subjects with locally advanced or metastatic breast cancer with a deleterious germline BRCA 1 or BRCA 2 mutation. Subjects will be assigned to either Cohort 1 or 2 based on prior chemotherapy for metastatic disease:

• Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for metastatic disease with disease progression > 8 weeks following the last dose of platinum; or

• Cohort 2) Subjects who have received > 2 prior chemotherapy regimens for metastatic disease and who have had no prior platinum therapy for metastatic disease

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medivation, Inc.; Pfizer
• Collaborators: Medivation is now a wholly owned subsidiary of Pfizer Inc.; Medivation, Inc.; Myriad Genetic Laboratories, Inc.
• Treatments: Talazoparib

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed carcinoma of the breast

• Locally advanced and/or metastatic disease

• Deleterious or pathogenic germline BRCA 1 or BRCA 2 mutation

• Prior chemotherapy: Cohort 1) PR or CR to prior platinum-containing regimen for metastatic disease with disease progression > 8 weeks following the last dose of platinum; or Cohort 2) > 2 prior chemotherapy regimens for metastatic disease and no prior platinum for metastatic disease

• ECOG performance status ≤ 1

• Have adequate organ function

Exclusion Criteria:

• Prior enrollment into a clinical trial of a PARP inhibitor

• CNS metastasis except adequately treated brain metastasis documented by baseline CT or MRI scan that has not progressed since previous scans and that does not require corticosteroids for management of CNS symptoms

• Prior malignancy except for prior BRCA-associated cancer as long as there is no current evidence of the prior cancer, carcinoma in situ of the cervix or non-melanoma skin cancer, and a cancer diagnosed and definitively treated >5 years prior to study enrollment with no subsequent evidence of recurrence

• Known to be HIV positive, active hepatitis C virus, or active hepatitis B virus

• Known hypersensitivity to any of the components of talazoparib